深圳龙瑞药业

Shenzhen Longrui Pharmaceutical is a clinical-stage biopharmaceutical company based in Shenzhen, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2017, the company focuses on high-unmet-need areas including oncology, metabolic disorders, and autoimmune diseases. Its lead pipeline candidates include LR0811, a selective CDK4/6 inhibitor currently in Phase 2 trials for advanced breast cancer, and LR0711, a URAT1 inhibitor being developed for gout and hyperuricemia. Longrui leverages its internal R&D capabilities and a team of experienced industry veterans to advance a diverse portfolio of targeted therapies. The company has secured significant funding from prominent Chinese venture capital firms to support its clinical programs and expansion.